Document Detail


Central serous chorioretinopathy: update on pathophysiology and treatment.
MedLine Citation:
PMID:  23410821     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Recent technological advances--new pathophysiological insights, new imaging techniques for diagnosis and management, and new treatments--have led to an improved understanding of central serous chorioretinopathy (CSC). The primary role of the choroid has become more widely accepted with widespread use of indocyanine green angiography. Optical coherence tomography (OCT), and particularly enhanced depth imaging OCT, demonstrate a thickened and engorged choroid. Adaptive optics, fundus autofluorescence, multifocal electroretinography, microperimetry, and contrast sensitivity testing reveal that patients with even a mild course suffer previously undetected anatomic and functional loss. Although focal laser and photodynamic therapy are the current standard of care for persistent subretinal fluid in CSC, they are not appropriate in all cases, and the optimal timing of intervention remains unclear.
Authors:
Benjamin Nicholson; Jason Noble; Farzin Forooghian; Catherine Meyerle
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Survey of ophthalmology     Volume:  58     ISSN:  1879-3304     ISO Abbreviation:  Surv Ophthalmol     Publication Date:    2013 Mar-Apr
Date Detail:
Created Date:  2013-02-15     Completed Date:  2013-06-07     Revised Date:  2014-03-06    
Medline Journal Info:
Nlm Unique ID:  0404551     Medline TA:  Surv Ophthalmol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  103-26     Citation Subset:  IM    
Copyright Information:
Published by Elsevier Inc.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Central Serous Chorioretinopathy / diagnosis,  physiopathology*,  therapy*
Coloring Agents / diagnostic use
Fluorescein Angiography
Humans
Indocyanine Green / diagnostic use
Laser Coagulation
Photochemotherapy
Tomography, Optical Coherence
Visual Field Tests
Grant Support
ID/Acronym/Agency:
Z99 EY999999/EY/NEI NIH HHS
Chemical
Reg. No./Substance:
0/Coloring Agents; IX6J1063HV/Indocyanine Green
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  How Technology Influences the Therapeutic Process: Evaluation of the Patient-Therapist Relationship ...
Next Document:  Pregnancy-associated Retinal Diseases and Their Management.